サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1758887

甲状腺未分化がん薬の世界市場

Anaplastic Thyroid Cancer Drugs

出版日
ページ情報
英文 142 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.69円
甲状腺未分化がん薬の世界市場
出版日: 2025年06月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 142 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

甲状腺未分化がん薬の世界市場は2030年までに14億米ドルに到達

2024年に9億7,540万米ドルと推定される甲状腺未分化がん薬の世界市場は、分析期間2024-2030年にCAGR 5.9%で成長し、2030年には14億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法は、CAGR 6.9％を記録し、分析期間終了時には9億1,210万米ドルに達すると予測されます。新規治療分野の成長率は、分析期間のCAGRで4.2％と推定されます。

米国市場は2億5,640万米ドルと推定、中国はCAGR 5.8％で成長予測

米国の甲状腺未分化がん薬市場は、2024年に2億5,640万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.8%として、2030年までに2億2,160万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.7%と4.9%と予測されています。欧州では、ドイツがCAGR 4.7%で成長すると予測されています。

世界の甲状腺未分化がん薬市場- 主要動向と促進要因のまとめ

なぜ世界的に甲状腺未分化がん治療に注目が集まっているのか？

甲状腺未分化がん（ATC）は、まれではあるが、甲状腺悪性腫瘍の中でも最も侵攻性が高く致死的であるため、効果的な薬剤開発が世界的に重要視されています。従来、甲状腺がんは進行が早く、従来の治療法に抵抗性があり、早期に転移する傾向があるため、治療の選択肢は極めて限られていました。しかし、この重大なアンメット・ニーズに対して研究者や製薬会社がますます関心を向けるようになり、潮目が変わりつつあります。分子腫瘍学の進歩と診断能力の向上により、ATCの早期発見と分類が可能となり、より的を絞った管理アプローチが育まれています。ヘルスケアシステムは現在、希少がんや死亡率の高いがんを優先的に扱うようになっており、実験的治療に対する資金提供の増加や規制当局の迅速な対応につながっています。公的医療機関も民間企業も同様に、商業的リターンが限られているため、以前は治療不可能とみなされていた疾患の治療に投資することの重要性を認識しています。

さらに、臨床医や患者の意識の高まりが、新規のATC治療薬に対する需要を加速させています。症状が他の甲状腺疾患と類似していることが多いATCは、歴史的に診断の遅れに悩まされてきたが、画像診断と遺伝子プロファイリングの改善により、より正確でタイムリーな発見が可能になりつつあります。これにより、治療介入の窓口が広がり、迅速かつ効果的に作用する薬剤の必要性が強調されています。患者支援団体や希少がん財団も、ATC研究への注目と支援を求めてロビー活動を展開し、より強い役割を果たしています。これと並行して、製薬会社は、税制上の優遇措置や市場独占権を提供する希少疾病用医薬品の優遇措置を活用し、この希少がんに対する医薬品開発に資源を投入しています。ATCに伴う緊急性は、科学的・政策的な機運と相まって、治療の展望を再構築し、かつては絶望的であったこの診断に直面する患者にとって希望の新時代の到来を告げています。

新しい治療アプローチは甲状腺未分化がんの薬剤パイプラインをどのように再構築しているか？

甲状腺未分化がんの薬剤開発パイプラインは、この疾患の原因となる遺伝的・分子的異常に対する理解の拡大により、顕著な変貌を遂げつつあります。ATCの進行を止められないことが多い従来の化学療法とは異なり、新たな治療法は、腫瘍の成長を促す特定の変異や経路を標的とする精密医療に焦点を当てています。近年の大きなブレークスルーのひとつは、BRAF、TP53、TERTプロモーター領域などの遺伝子における変異の同定です。これらの発見により、異常な細胞シグナル伝達プロセスを破壊するキナーゼ阻害剤を含む標的治療への扉が開かれました。例えばBRAF V600E変異を標的とする薬剤は、特にMEK阻害剤と併用した場合に臨床試験で有望視されています。これらの併用療法は、複数のメカニズムで同時にがん細胞を攻撃することで、優れた有効性を示しています。

標的療法に加えて、この分野では免疫療法に基づくアプローチが急増しています。他のいくつかのがんの治療に革命をもたらした免疫チェックポイント阻害剤は、現在ATCでの有効性が評価されています。甲状腺腫瘍の免疫学的に"冷たい"性質が課題となっているが、初期段階の研究では、チェックポイント阻害剤と他の薬剤を併用することで、免疫系の認識と反応が高まる可能性が示唆されています。さらに、次世代シーケンサーの開発により、個々の腫瘍プロファイルに基づいた個別化治療レジメンの開発が容易になりつつあります。薬剤の再利用（リパーポージング）も盛んになってきており、いくつかの既存の抗がん剤が、共通の分子経路に対する活性を持つことから、ATCに対する有効性が試験されています。このような革新的な戦略により、治療のパラダイムは、非特異的な緩和ケアから、より戦略的な延命アプローチへと徐々に移行しつつあります。臨床試験の枠組みがATCのような希少で進行の速いがんに対応できるように進化するにつれ、より多くの患者が実験的薬剤にアクセスできるようになり、データ収集と治療上のブレークスルーの両方が加速しています。

地域間でのATC治療薬へのアクセス拡大における課題と機会とは？

効果的な甲状腺未分化がん薬への世界のアクセス拡大には、課題と新たな機会の両方が複雑に絡み合っています。主な障壁の一つは、開発・商業化にかかるコストの高さであり、特に患者数が少ないことや、疾患の進行に伴う緊急性を考慮すると、開発・商業化のコストが高いことが挙げられます。その結果、多くの有望な治療法は、医療制度が革新的な治療法を提供する余裕を持ち、迅速な薬事承認をサポートするインフラを持つ高所得国でのみ、当初は利用可能です。これとは対照的に、中低所得国では先進的な診断や臨床試験へのアクセスが限られているため、診断が遅れたり、見逃されたりすることが多く、最先端の治療薬が利用できないことが多いです。新規治療が利用可能であっても、保険や公的ヘルスケア補助がなければ、標的治療や免疫療法の費用は高額になりかねないです。

しかし、国際的な協力により、このような格差の一部が解消されつつあります。研究者、腫瘍医、政策立案者からなる世界・コンソーシアムは、臨床ガイドラインを調和させ、国境を越えてデータを共有するために協力しており、効果的な治療戦略を特定し、多様な集団における成功を再現することを容易にしています。さらに、希少疾患治療薬の早期承認パスウェイに関する規制当局の協力も進んでおり、ATC薬の新興市場への参入を効率化することができます。非政府組織や希少がんアライアンスも、患者支援プログラム、ドラッグ・アクセス・イニシアチブ、より公平な医療提供を可能にする教育普及活動の提供に乗り出しています。一方、製薬会社は、段階的価格設定モデルやコンパッショネート・ユース・プログラムの導入を奨励され、場合によっては義務付けられています。このような開発は、アクセスを改善するだけでなく、より包括的な研究エコシステムを促進し、十分な治療を受けていない患者グループも医薬品開発の一端を担うようになっています。

甲状腺未分化がん薬市場の成長を促す主な要因とは？

甲状腺未分化がん薬市場の成長は、科学の進歩、規制の枠組みの変化、治療哲学の進化を背景とするいくつかの重要な要因によって牽引されています。最も重要な促進要因の一つは、分子生物学の急速な進歩であり、これによりATCは治療不可能な診断から遺伝学的に定義された介入対象へと変貌を遂げました。腫瘍ゲノム・プロファイリングやリキッドバイオプシーなどのプレシジョン・オンコロジー・ツールは、治療方針の決定に不可欠なものとなり、腫瘍医は変異の状態に基づいて最も適切な薬剤の組み合わせを選択できるようになりました。その結果、従来の化学療法に比べて治療成績が向上するだけでなく、全身毒性も軽減される標的療法が台頭してきました。同時に、より広範な甲状腺がん研究のための臨床試験にATC患者を組み入れることが増え、利用可能な知識ベースと治療選択肢が拡大しています。

規制当局もまた、市場の成長を促す上で極めて重要な役割を果たしています。希少疾病用医薬品の指定、迅速承認、拡大アクセスプログラムは、製薬会社がATCのための医薬品開発に投資する動機付けとなっています。これらの規制上の利点により、市場投入までの時間が短縮され、独占期間が延長されるため、ニッチな市場規模であるにもかかわらず、この分野はより商業的に実行可能なものとなっています。さらに、デジタルカルテやがん登録から得られる実臨床エビデンスの利用可能性が高まることで、新たな治療法の有効性が検証され、より広範な導入が促されています。ヘルスケア提供の観点からは、がん治療の集学的センターへの集中化により、専門家の意見や実験的治療への一貫したアクセスが確保されつつあります。個別化医療に対する患者の要求は、希少がんや侵攻性がんに対する世界の意識の高まりと相まって、ATC治療開発を優先するようヘルスケアシステムを後押ししています。これらの要因が相まって、ATC治療薬市場の技術革新とアクセスが加速し、かつては選択肢がほとんどなかった患者に新たな希望をもたらしています。

セグメント

製品（化学療法、新規療法）;エンドユース（病院エンドユース、クリニックエンドユース、その他エンドユース）

調査対象企業の例

  • AbbVie Inc.
  • AffyImmune Therapeutics, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Genentech, Inc.
  • Hikma Pharmaceuticals PLC
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Plexxikon Inc.
  • Sanofi S.A.
  • Seagen Inc.
  • Takeda Pharmaceutical Company

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP36162

Global Anaplastic Thyroid Cancer Drugs Market to Reach US$1.4 Billion by 2030

The global market for Anaplastic Thyroid Cancer Drugs estimated at US$975.4 Million in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$912.1 Million by the end of the analysis period. Growth in the Novel Therapy segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$256.4 Million While China is Forecast to Grow at 5.8% CAGR

The Anaplastic Thyroid Cancer Drugs market in the U.S. is estimated at US$256.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$221.6 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Anaplastic Thyroid Cancer Drugs Market - Key Trends & Drivers Summarized

Why Is There a Surge in Focus on Anaplastic Thyroid Cancer Treatments Globally?

Anaplastic thyroid cancer (ATC), though rare, is among the most aggressive and lethal forms of thyroid malignancy, prompting a significant global push for effective drug development. Traditionally, treatment options for ATC have been extremely limited due to the cancer’s rapid progression, resistance to conventional therapies, and tendency to metastasize early. However, the tide is shifting as researchers and pharmaceutical companies increasingly turn their attention toward this critical unmet need. Advances in molecular oncology and improved diagnostic capabilities have allowed for earlier identification and classification of ATC, fostering a more targeted approach to its management. Healthcare systems are now prioritizing rare and high-mortality cancers, leading to increased funding and faster regulatory pathways for experimental treatments. Public health institutions and private enterprises alike are recognizing the importance of investing in therapies for diseases previously deemed untreatable due to limited commercial returns.

Moreover, rising awareness among clinicians and patients is accelerating the demand for novel ATC drugs. With symptoms often resembling those of other thyroid disorders, ATC has historically suffered from delayed diagnosis, but improved imaging and genetic profiling are enabling more accurate and timely detection. This has helped expand the window for therapeutic intervention and has emphasized the need for drugs capable of acting quickly and effectively. Patient advocacy groups and rare cancer foundations are also playing a stronger role, lobbying for attention and support for ATC research. In parallel, pharmaceutical companies are leveraging orphan drug incentives, which offer tax benefits and market exclusivity, to commit resources toward drug development for this rare cancer. The urgency associated with ATC, combined with scientific and policy momentum, is reshaping the therapeutic landscape and ushering in a new era of hope for patients facing this once-hopeless diagnosis.

How Are New Therapeutic Approaches Reshaping the Anaplastic Thyroid Cancer Drug Pipeline?

The drug development pipeline for anaplastic thyroid cancer is undergoing a notable transformation, driven by an expanding understanding of the genetic and molecular abnormalities that fuel the disease. Unlike conventional chemotherapy, which often fails to halt ATC progression, emerging treatments are focused on precision medicine-targeting the specific mutations and pathways that drive tumor growth. One of the major breakthroughs in recent years has been the identification of mutations in genes such as BRAF, TP53, and TERT promoter regions. These discoveries have opened the door to targeted therapies, including kinase inhibitors that can disrupt aberrant cell signaling processes. Drugs targeting BRAF V600E mutations, for instance, have shown promise in clinical trials, especially when used in combination with MEK inhibitors. These combination therapies are demonstrating superior efficacy by attacking cancer cells through multiple mechanisms simultaneously.

In addition to targeted therapies, the field is witnessing a surge in immunotherapy-based approaches. Immune checkpoint inhibitors, which have revolutionized the treatment of several other cancers, are now being evaluated for their effectiveness in ATC. While the immunologically "cold" nature of thyroid tumors has posed challenges, early-stage studies suggest that combining checkpoint inhibitors with other agents may enhance immune system recognition and response. Furthermore, advancements in next-generation sequencing are facilitating the development of personalized treatment regimens based on individual tumor profiles. Drug repurposing is also gaining traction, with several existing cancer drugs being tested for efficacy against ATC due to their activity on shared molecular pathways. These innovative strategies are gradually shifting the treatment paradigm from non-specific, palliative care to a more strategic, life-prolonging approach. As clinical trial frameworks evolve to accommodate rare and fast-moving cancers like ATC, more patients are gaining access to experimental drugs, accelerating both data collection and therapeutic breakthroughs.

What Are the Challenges and Opportunities in Expanding Access to ATC Drugs Across Regions?

Expanding global access to effective anaplastic thyroid cancer drugs presents a complex landscape of both challenges and emerging opportunities. One of the primary barriers is the high cost of development and commercialization, particularly given the small patient population and the urgency associated with disease progression. As a result, many promising treatments are initially only available in high-income countries where healthcare systems can afford innovative therapies and have the infrastructure to support expedited regulatory approvals. In contrast, low- and middle-income countries often struggle with limited access to advanced diagnostics and clinical trials, resulting in delayed or missed diagnoses and reduced availability of cutting-edge drugs. Even when novel treatments are available, the cost of targeted therapies and immunotherapy can be prohibitive without robust insurance or public healthcare subsidies.

However, international collaboration is beginning to address some of these disparities. Global consortia of researchers, oncologists, and policymakers are working together to harmonize clinical guidelines and share data across borders, making it easier to identify effective treatment strategies and replicate successes in diverse populations. Additionally, regulatory agencies are increasingly cooperating on accelerated approval pathways for rare disease therapies, which can help streamline the entry of ATC drugs into emerging markets. Non-governmental organizations and rare cancer alliances are also stepping in to provide patient assistance programs, drug access initiatives, and educational outreach that enable more equitable care delivery. Meanwhile, pharmaceutical companies are being encouraged-and in some cases mandated-to implement tiered pricing models and compassionate use programs. These developments are not only improving access but are also fostering a more inclusive research ecosystem where underrepresented patient groups are part of the drug development narrative.

What Key Factors Are Driving the Growth of the Anaplastic Thyroid Cancer Drugs Market?

The growth in the anaplastic thyroid cancer drugs market is driven by several key factors anchored in scientific advancement, changing regulatory frameworks, and evolving treatment philosophies. One of the most significant drivers is the rapid progress in molecular biology, which has transformed ATC from an untreatable diagnosis into a genetically defined target for intervention. Precision oncology tools, such as tumor genomic profiling and liquid biopsies, have become integral in guiding treatment decisions, enabling oncologists to select the most appropriate drug combinations based on mutation status. This has led to the rise of targeted therapies that not only improve outcomes but also reduce systemic toxicity compared to traditional chemotherapy. Simultaneously, the increasing inclusion of ATC patients in clinical trials for broader thyroid cancer studies is expanding the knowledge base and treatment options available.

Regulatory bodies are also playing a pivotal role in stimulating market growth. Orphan drug designations, fast-track approvals, and expanded access programs are incentivizing pharmaceutical companies to invest in drug development for ATC. These regulatory advantages reduce time-to-market and provide extended exclusivity, making the segment more commercially viable despite its niche size. Additionally, the growing availability of real-world evidence from digital health records and cancer registries is helping validate the effectiveness of emerging therapies, encouraging broader adoption. From a healthcare delivery standpoint, the centralization of cancer care into multidisciplinary centers is ensuring more consistent access to expert opinion and experimental treatments. Patient-driven demand for personalized medicine, coupled with rising global awareness about rare and aggressive cancers, is also pushing healthcare systems to prioritize ATC treatment development. Altogether, these factors are converging to accelerate innovation and access in the ATC drugs market, providing new hope to patients where few options once existed.

SCOPE OF STUDY:

The report analyzes the Anaplastic Thyroid Cancer Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Chemotherapy, Novel Therapy); End-Use (Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • AffyImmune Therapeutics, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Genentech, Inc.
  • Hikma Pharmaceuticals PLC
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Plexxikon Inc.
  • Sanofi S.A.
  • Seagen Inc.
  • Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Anaplastic Thyroid Cancer Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Aggressive Thyroid Malignancies Spurs Demand for Targeted Anaplastic Thyroid Cancer (ATC) Therapies
    • Advancements in Genomic Profiling and Precision Oncology Strengthen the Business Case for Personalized ATC Drug Development
    • Here's How Breakthroughs in Kinase Inhibitors and Immunotherapies Propel Growth in Advanced Treatment Options
    • Growing Use of Combination Therapies Expands the Addressable Market for Multi-Mechanism Drug Regimens
    • Surge in Late-Stage Diagnoses Throws the Spotlight on Urgent Need for Rapid-Acting and Life-Extending Treatments
    • Here's the Story: FDA Accelerated Approvals and Orphan Drug Designations Fuel Innovation and Market Entry
    • Rising Healthcare Infrastructure in Emerging Markets Generates Opportunities for Improved Drug Accessibility
    • Integration of Real-World Evidence and Patient Registries Strengthens Post-Marketing Surveillance and Drug Optimization
    • Technological Advancements in Liquid Biopsy and Molecular Diagnostics Drive Early Detection and Therapy Matching
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anaplastic Thyroid Cancer Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Novel Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Novel Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anaplastic Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Product - Chemotherapy and Novel Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Product - Percentage Breakdown of Value Sales for Chemotherapy and Novel Therapy for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Product - Chemotherapy and Novel Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Product - Percentage Breakdown of Value Sales for Chemotherapy and Novel Therapy for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Anaplastic Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Product - Chemotherapy and Novel Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Product - Percentage Breakdown of Value Sales for Chemotherapy and Novel Therapy for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Anaplastic Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Product - Chemotherapy and Novel Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Product - Percentage Breakdown of Value Sales for Chemotherapy and Novel Therapy for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Anaplastic Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Product - Chemotherapy and Novel Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Product - Percentage Breakdown of Value Sales for Chemotherapy and Novel Therapy for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Anaplastic Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Product - Chemotherapy and Novel Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Product - Percentage Breakdown of Value Sales for Chemotherapy and Novel Therapy for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Anaplastic Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Product - Chemotherapy and Novel Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Product - Percentage Breakdown of Value Sales for Chemotherapy and Novel Therapy for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Product - Chemotherapy and Novel Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Product - Percentage Breakdown of Value Sales for Chemotherapy and Novel Therapy for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Anaplastic Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Product - Chemotherapy and Novel Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Product - Percentage Breakdown of Value Sales for Chemotherapy and Novel Therapy for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Product - Chemotherapy and Novel Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Rest of Europe 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Product - Percentage Breakdown of Value Sales for Chemotherapy and Novel Therapy for the Years 2025 & 2030
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Anaplastic Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Product - Chemotherapy and Novel Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Product - Percentage Breakdown of Value Sales for Chemotherapy and Novel Therapy for the Years 2025 & 2030
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 60: Rest of World Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by Product - Chemotherapy and Novel Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of World 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by Product - Percentage Breakdown of Value Sales for Chemotherapy and Novel Therapy for the Years 2025 & 2030
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Anaplastic Thyroid Cancer Drugs by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of World 6-Year Perspective for Anaplastic Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION